VALIDATION OF IN-VITRO ANTI-CANCER ACTIVITY OF SIDDHA METALLO-MINERAL FORMULATION NANDHI MEZHUGU AGAINST TM3 CELL LINES.

Abstract

Background: Testicular cancer is the most common malignancy among men between 14 and 44 years of age, and its incidence has risen over the past two decades. Nandhi Mezhuguis a Siddha herbo-mineral formulation widely used to treat various cancers and testicular cancer is one among them. Due to lack of scientific evidence, the present study was envisioned to evaluate the anti-cancer activity of Nandhi Mezhugu in the TM3 cell lines.

Methods: TM3 cell lines were used to assess the antiproliferative activity of Nandhi Mezhugu using the MTT assay, apoptosis by Acridine Orange (Ao) and Ethidium Bromide (Etbr) Double Staining and Annexin V flow cytometry.

Results: Nandhi Mezhugu produced dose-dependent cytotoxic effects against TM3 cell lines with an LC50 value of 102.2946 µg/mL. Further investigation, using Apoptosis by Ao and EtBr showed the apoptotic changes by colour change and chromatin condensation. Annexin V flow cytometry, equivalently revealed the late apoptotic effect, with a percentage value of 21.40.

Conclusion: Thus, the current study evaluates the effectiveness of Nandhi Mezhugu against Testicular cancer. Future RCT or Clinical trials will explore the effectiveness and safety of Nandhi Mezhugu in human subjects